Patents by Inventor Jeffrey Browning

Jeffrey Browning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050118629
    Abstract: Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 29, 2004
    Publication date: June 2, 2005
    Inventors: Jeffrey Browning, Yves Chichportiche
  • Publication number: 20050112666
    Abstract: Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 26, 2005
    Inventors: Jeffrey Browning, Yves Chichportiche
  • Publication number: 20050100548
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Application
    Filed: December 21, 2004
    Publication date: May 12, 2005
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Patent number: 6869605
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: March 22, 2005
    Assignee: Biogen Idec Ma Inc.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Publication number: 20050037003
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Application
    Filed: February 15, 2002
    Publication date: February 17, 2005
    Inventors: Jeffrey Browning, Christopher Benjamin, Paula Hochman
  • Publication number: 20040110218
    Abstract: BMOG, A Novel Protein Member of the Myelin-Oligodendrocyte Glycoprotein Family which is expressed by germinal center B cells and Its Use For Immunomodulatory Purposes
    Type: Application
    Filed: October 28, 2003
    Publication date: June 10, 2004
    Inventor: Jeffrey Browning
  • Publication number: 20040033225
    Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
    Type: Application
    Filed: March 14, 2003
    Publication date: February 19, 2004
    Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
  • Publication number: 20020165156
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: February 15, 2002
    Publication date: November 7, 2002
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Publication number: 20020039580
    Abstract: Methods for high level expression of active lymphotoxin-&bgr; receptor immunoglobulin chimeric proteins and their purification.
    Type: Application
    Filed: January 23, 2001
    Publication date: April 4, 2002
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Publication number: 20020037852
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Application
    Filed: July 24, 2001
    Publication date: March 28, 2002
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Publication number: 20020001585
    Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
    Type: Application
    Filed: April 9, 2001
    Publication date: January 3, 2002
    Inventors: Jeffrey Browning, Maryann Puglielli, Rafi Ahmed
  • Patent number: 5795964
    Abstract: This invention relates to lymphotoxin-.beta., a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-.beta. and other peptides such as lymphotoxin-.alpha. and to complexes comprising multiple subunits of lymphotoxin-.beta.. These proteins and complexes are useful in holding LT-.alpha. formed within the cell on the cell surface where the LT-.alpha./LT-.beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-.alpha./LT-.beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-.beta..
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 18, 1998
    Assignees: Biogen, Inc., University of California
    Inventors: Jeffrey Browning, Carl F. Ware
  • Patent number: 5670149
    Abstract: This invention relates to lymphotoxin-.beta., a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PNA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-.beta. and other peptides such as lymphotoxin-.alpha. and to complexes comprising multiple subunits of lymphotoxin-.beta.. These proteins and complexes are useful in holding LT-.alpha. formed within the cell on the cell surface where the LT-.alpha./LT-.beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-.alpha./LT-.beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-.beta..
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 1997
    Assignees: Biogen, Inc., The University of California
    Inventors: Jeffrey Browning, Carl F. Ware
  • Patent number: 5661004
    Abstract: This invention relates to lymphotoxin-.beta., a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-.beta. and other peptides such as lymphotoxin-.alpha. and to complexes comprising multiple subunits of lymphotoxin-.beta.. These proteins and complexes are useful in holding LT-.alpha. formed within the cell on the cell surface where the LT-.alpha./LT.beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-.alpha./LT-.beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-.beta..
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignees: Biogen, Inc., University of California
    Inventors: Jeffrey Browning, Carl F. Ware